BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gan-Or Z, Liong C, Alcalay RN. GBA-Associated Parkinson's Disease and Other Synucleinopathies. Curr Neurol Neurosci Rep 2018;18:44. [PMID: 29884970 DOI: 10.1007/s11910-018-0860-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 15.8] [Reference Citation Analysis]
Number Citing Articles
1 Asthana J, Shravage BV. Exploring therapeutic potential of mitophagy modulators using Drosophila models of Parkinson’s disease. Front Aging Neurosci 2022;14:986849. [DOI: 10.3389/fnagi.2022.986849] [Reference Citation Analysis]
2 Pavelka L, Rauschenberger A, Landoulsi Z, Pachchek S, Marques T, Gomes CP, Glaab E, May P, Krüger R, on behalf of the NCER-PD Consortium. Body-First Subtype of Parkinson’s Disease with Probable REM-Sleep Behavior Disorder Is Associated with Non-Motor Dominant Phenotype. JPD 2022. [DOI: 10.3233/jpd-223511] [Reference Citation Analysis]
3 Jensen-roberts S, Myers TL, Auinger P, Cannon P, Rowbotham HM, Coker D, Chanoff E, Soto J, Pawlik M, Amodeo K, Sharma S, Valdovinos B, Wilson R, Sarkar A, Mcdermott MP, Alcalay RN, Biglan K, Kinel D, Tanner C, Winter-evans R, Augustine EF, Holloway RG, Dorsey ER, Schneider RB. A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease. Neurol Genet 2022;8:e200008. [DOI: 10.1212/nxg.0000000000200008] [Reference Citation Analysis]
4 Qiu J, Peng G, Tang Y, Liu H, Wei L, Su Y, Lin Y, Dai W, Zhang Z, Chen X, Ding L, Guo W, Zhu X, Xu P, Mo M. Lipid profiles in the cerebrospinal fluid of rats with 6-hydroxydopamine-induced lesions as a model of Parkinson's disease.. [DOI: 10.21203/rs.3.rs-2098905/v1] [Reference Citation Analysis]
5 Valencia J, Ferreira M, Merino-torres JF, Marcilla A, Soriano JM. The Potential Roles of Extracellular Vesicles as Biomarkers for Parkinson’s Disease: A Systematic Review. IJMS 2022;23:11508. [DOI: 10.3390/ijms231911508] [Reference Citation Analysis]
6 Al-azzawi ZA, Arfaie S, Gan-or Z. GBA1 and The Immune System: A Potential Role in Parkinson’s Disease? JPD 2022;12:S53-S64. [DOI: 10.3233/jpd-223423] [Reference Citation Analysis]
7 Parlar SC, Grenn FP, Kim JJ, Blauwendraat C, Gan-or Z. Classification of GBA1 variants in Parkinson’s disease; the GBA1-PD browser.. [DOI: 10.1101/2022.09.27.22280421] [Reference Citation Analysis]
8 Mo M, Qiu J, Tang Y, Wei L, Peng G, Lin Y, Dai W, Zhang Z, Chen X, Liu H, Ding L, Guo W, Xu P. Lipid metabolism disorder in cerebrospinal fluid related to Parkinson’s disease.. [DOI: 10.21203/rs.3.rs-2039971/v1] [Reference Citation Analysis]
9 Vieira SRL, Schapira AHV. Glucocerebrosidase mutations and Parkinson disease. J Neural Transm (Vienna) 2022. [PMID: 35932311 DOI: 10.1007/s00702-022-02531-3] [Reference Citation Analysis]
10 Xiao X, Yang Q, Wen Y, Jiao B, Liao X, Zhou Y, Weng L, Liu H, Xu T, Zhu Y, Guo L, Zhou L, Wang X, Liu X, Bi X, Liu Y, Zhang S, Zhang W, Li J, Tang B, Shen L. Genetics of progressive supranuclear palsy in a Chinese population. Neurobiol Dis 2022;172:105819. [PMID: 35842134 DOI: 10.1016/j.nbd.2022.105819] [Reference Citation Analysis]
11 Liu L, Li J, Quan W, Qin Y, Zhang Q, Pei X, Su H, Xu J, Chen J. Effect of GBA gene variants on clinical characteristics of dementia with Lewy bodies: a review and meta-analyses. Neurol Sci 2022;43:3541-3550. [DOI: 10.1007/s10072-022-06031-w] [Reference Citation Analysis]
12 Menon S, Armstrong S, Hamzeh A, Visanji NP, Sardi SP, Tandon A. Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies. Front Neurol 2022;13:852003. [DOI: 10.3389/fneur.2022.852003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Abdelgawad A, Rahayel S, Zheng Y, Tremblay C, Vo A, Misic B, Dagher A. Predicting longitudinal brain atrophy in Parkinson’s disease using a Susceptible-Infected-Removed agent-based model.. [DOI: 10.1101/2022.05.01.22274521] [Reference Citation Analysis]
14 Huang J, Cheng Y, Li C, Shang H. Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis. Transl Neurodegener 2022;11:21. [PMID: 35395825 DOI: 10.1186/s40035-022-00294-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zheng W, Fan D. Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications. Front Aging Neurosci 2022;14:851135. [DOI: 10.3389/fnagi.2022.851135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Abbasi N, Tremblay C, Rajimehr R, Yu E, Markello RD, Shafiei G, Khatibi N, Jahanshad N, Thompson PM, Gan-or Z, Misic B, Dagher A, The ENIGMA-Parkinson’s study. Neuroanatomical correlates of polygenic risk for Parkinson’s Disease.. [DOI: 10.1101/2022.01.17.22269262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Vieira SRL, Schapira AHV. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radic Biol Med 2021;175:42-55. [PMID: 34450264 DOI: 10.1016/j.freeradbiomed.2021.08.230] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Wang J, Cao H. Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases. Int J Mol Sci 2021;22:10766. [PMID: 34639106 DOI: 10.3390/ijms221910766] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
19 Johnson ME, Bergkvist L, Stetzik L, Steiner JA, Meyerdirk L, Schulz E, Wolfrum E, Luk KC, Wesson DW, Krainc D, Brundin P. Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological α-synuclein spread in the prodromal preformed fibrils model in young mice. Neurobiol Dis 2021;159:105513. [PMID: 34536552 DOI: 10.1016/j.nbd.2021.105513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Torrealba-Acosta G, Yu E, Lobo-Prada T, Ruíz-Martínez J, Gorostidi-Pagola A, Gan-Or Z, Carazo-Céspedes K, Trempe JF, Mata IF, Fornaguera-Trías J. Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease. Front Neurol 2021;12:656342. [PMID: 34421783 DOI: 10.3389/fneur.2021.656342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ledda C, Artusi CA, Montanaro E, Martone T, Zibetti M, Lopiano L. G325R GBA mutation in Parkinson's disease: Disease course and long-term DBS outcome. Brain Stimul 2021;14:1169-71. [PMID: 34375692 DOI: 10.1016/j.brs.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Avisar H, Guardia-Laguarta C, Area-Gomez E, Surface M, Chan AK, Alcalay RN, Lerner B. Lipidomics Prediction of Parkinson's Disease Severity: A Machine-Learning Analysis. J Parkinsons Dis 2021;11:1141-55. [PMID: 33814463 DOI: 10.3233/JPD-202476] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
23 Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T. Progress towards therapies for disease modification in Parkinson's disease. Lancet Neurol 2021;20:559-72. [PMID: 34146514 DOI: 10.1016/S1474-4422(21)00061-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 30.0] [Reference Citation Analysis]
24 Schultz EM, Jones TJ, Xu S, Dean DD, Zechmann B, Barr KL. Cerebral Organoids Derived from a Parkinson's Patient Exhibit Unique Pathogenesis from Chikungunya Virus Infection When Compared to a Non-Parkinson's Patient. Pathogens 2021;10:913. [PMID: 34358063 DOI: 10.3390/pathogens10070913] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 Gomez-Larrauri A, Das Adhikari U, Aramburu-Nuñez M, Custodia A, Ouro A. Ceramide Metabolism Enzymes-Therapeutic Targets against Cancer. Medicina (Kaunas) 2021;57:729. [PMID: 34357010 DOI: 10.3390/medicina57070729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
26 Day JO, Mullin S. The Genetics of Parkinson's Disease and Implications for Clinical Practice. Genes (Basel) 2021;12:1006. [PMID: 34208795 DOI: 10.3390/genes12071006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 17.0] [Reference Citation Analysis]
27 Custodia A, Aramburu-Núñez M, Correa-Paz C, Posado-Fernández A, Gómez-Larrauri A, Castillo J, Gómez-Muñoz A, Sobrino T, Ouro A. Ceramide Metabolism and Parkinson's Disease-Therapeutic Targets. Biomolecules 2021;11:945. [PMID: 34202192 DOI: 10.3390/biom11070945] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
28 Rodrigues PS, Kale PP. Mini review - The role of Glucocerebrosidase and Progranulin as possible targets in the treatment of Parkinson's disease. Rev Neurol (Paris) 2021:S0035-3787(21)00567-1. [PMID: 34175090 DOI: 10.1016/j.neurol.2021.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Gialluisi A, Reccia MG, Modugno N, Nutile T, Lombardi A, Di Giovannantonio LG, Pietracupa S, Ruggiero D, Scala S, Gambardella S, Iacoviello L, Gianfrancesco F, Acampora D, D'Esposito M, Simeone A, Ciullo M, Esposito T; International Parkinson’s Disease Genomics Consortium (IPDGC). Identification of sixteen novel candidate genes for late onset Parkinson's disease. Mol Neurodegener 2021;16:35. [PMID: 34148545 DOI: 10.1186/s13024-021-00455-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
30 Gonzalez-Latapi P, Bayram E, Litvan I, Marras C. Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behav Sci (Basel) 2021;11:74. [PMID: 34068064 DOI: 10.3390/bs11050074] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
31 Prasuhn J, Brüggemann N. Genotype-driven therapeutic developments in Parkinson's disease. Mol Med 2021;27:42. [PMID: 33874883 DOI: 10.1186/s10020-021-00281-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
32 Weber M, Min SW, Truong T, Hung J, Dale S, Reichelt M, Ubhayakar S, Cain-Hom C, Baca M, Jiang Z, Li Q, Brendza R, Lin H, Kung C, Forrest WF, Quiason-Huynh C, Sandoval W, Chen B, Deng Y, Easton A, Foreman O, Sene A, Bingol B. Ocular phenotypes in a mouse model of impaired glucocerebrosidase activity. Sci Rep 2021;11:6079. [PMID: 33727605 DOI: 10.1038/s41598-021-85528-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Rebiai R, Givogri MI, Gowrishankar S, Cologna SM, Alford ST, Bongarzone ER. Synaptic Function and Dysfunction in Lysosomal Storage Diseases. Front Cell Neurosci 2021;15:619777. [PMID: 33746713 DOI: 10.3389/fncel.2021.619777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Moran EE, Bressman SB, Ortega RA, Raymond D, Nichols WC, Palmese CA, Elango S, Swan M, Shanker V, Perera I, Wang C, Zimmerman ME, Saunders-Pullman R. Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers. Front Neurol 2021;12:635958. [PMID: 33716938 DOI: 10.3389/fneur.2021.635958] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
35 Ntetsika T, Papathoma PE, Markaki I. Novel targeted therapies for Parkinson's disease. Mol Med 2021;27:17. [PMID: 33632120 DOI: 10.1186/s10020-021-00279-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
36 Hong M, Ho C, Zhang X, Zhang R, Liu Y. Dietary strategies may influence human nerves and emotions by regulating intestinal microbiota: an interesting hypothesis. Int J Food Sci Technol 2021;56:3311-21. [DOI: 10.1111/ijfs.14986] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
37 Koros C, Simitsi AM, Papagiannakis N, Bougea A, Prentakis A, Papadimitriou D, Pachi I, Antonelou R, Angelopoulou E, Beratis I, Bozi M, Papageorgiou SG, Trapali XG, Stamelou M, Stefanis L. Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. Parkinsonism Relat Disord 2021;84:1-4. [PMID: 33508700 DOI: 10.1016/j.parkreldis.2020.12.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Marino BLB, de Souza LR, Sousa KPA, Ferreira JV, Padilha EC, da Silva CHTP, Taft CA, Hage-Melim LIS. Parkinson's Disease: A Review from Pathophysiology to Treatment. Mini Rev Med Chem 2020;20:754-67. [PMID: 31686637 DOI: 10.2174/1389557519666191104110908] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 46.0] [Reference Citation Analysis]
39 Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10:4. [PMID: 33446243 DOI: 10.1186/s40035-020-00226-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]
40 Behl T, Kaur G, Fratila O, Buhas C, Judea-pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10. [DOI: 10.1186/s40035-020-00226-x] [Reference Citation Analysis]
41 García-Sanz P, M F G Aerts J, Moratalla R. The Role of Cholesterol in α-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease. Mov Disord 2021;36:1070-85. [PMID: 33219714 DOI: 10.1002/mds.28396] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
42 Tarakad A, Jankovic J. Recent advances in understanding and treatment of Parkinson's disease. Fac Rev 2020;9:6. [PMID: 33659938 DOI: 10.12703/b/9-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
43 Torrealba-acosta G, Yu E, Lobo-prada T, Ruiz-martínez J, Gorostidi-pagola A, Gan-or Z, Carazo-céspedes K, Fornaguera-trías J. Clinical and genetic analysis of Costa Rican patients with Parkinson’s disease.. [DOI: 10.1101/2020.09.29.20202432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Tayebi N, Lopez G, Do J, Sidransky E. Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism. Trends Mol Med 2020;26:913-23. [PMID: 32948448 DOI: 10.1016/j.molmed.2020.07.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
45 Lee CY, Yen HY, Zhong AW, Gao H. Resolving misalignment interference for NGS-based clinical diagnostics. Hum Genet 2021;140:477-92. [PMID: 32915251 DOI: 10.1007/s00439-020-02216-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
46 Alcalay RN, Wolf P, Chiang MSR, Helesicova K, Zhang XK, Merchant K, Hutten SJ, Scherzer C, Caspell-Garcia C, Blauwendraat C, Foroud T, Nudelman K, Gan-Or Z, Simuni T, Chahine LM, Levy O, Zheng D, Li G, Sardi SP; Parkinson’s Progression Markers Initiative. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. Ann Clin Transl Neurol 2020;7:1816-30. [PMID: 32888397 DOI: 10.1002/acn3.51164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
47 Tatiana S, Stanislav N, Darya K, Luiza G, Konstantin S, Sergey L, Elena V, Galina S, Nikolai V, Arthur K, Elena Z, Roman K, Tatiana U, Alexander S, Ekaterina Z, Anton E, Sofya P. Altered level of plasma exosomes in patients with Gaucher disease. Eur J Med Genet 2020;63:104038. [PMID: 32822875 DOI: 10.1016/j.ejmg.2020.104038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
48 Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-Ciga S, Tan M, Gibbs JR, Hernandez DG, Kumaran R, Langston R, Bonet-Ponce L, Alcalay RN, Hassin-Baer S, Greenbaum L, Iwaki H, Leonard HL, Grenn FP, Ruskey JA, Sabir M, Ahmed S, Makarious MB, Pihlstrøm L, Toft M, van Hilten JJ, Marinus J, Schulte C, Brockmann K, Sharma M, Siitonen A, Majamaa K, Eerola-Rautio J, Tienari PJ, Pantelyat A, Hillis AE, Dawson TM, Rosenthal LS, Albert MS, Resnick SM, Ferrucci L, Morris CM, Pletnikova O, Troncoso J, Grosset D, Lesage S, Corvol JC, Brice A, Noyce AJ, Masliah E, Wood N, Hardy J, Shulman LM, Jankovic J, Shulman JM, Heutink P, Gasser T, Cannon P, Scholz SW, Morris H, Cookson MR, Nalls MA, Gan-Or Z, Singleton AB; 23andMe Research Team. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain 2020;143:234-48. [PMID: 31755958 DOI: 10.1093/brain/awz350] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 46.5] [Reference Citation Analysis]
49 Krohn L, Ruskey JA, Rudakou U, Leveille E, Asayesh F, Hu MTM, Arnulf I, Dauvilliers Y, Högl B, Stefani A, Monaca CC, Abril B, Plazzi G, Antelmi E, Ferini-Strambi L, Heidbreder A, Boeve BF, Espay AJ, De Cock VC, Mollenhauer B, Sixel-Döring F, Trenkwalder C, Sonka K, Kemlink D, Figorilli M, Puligheddu M, Dijkstra F, Viaene M, Oertel W, Toffoli M, Gigli GL, Valente M, Gagnon JF, Desautels A, Montplaisir JY, Postuma RB, Rouleau GA, Gan-Or Z. GBA variants in REM sleep behavior disorder: A multicenter study. Neurology 2020;95:e1008-16. [PMID: 32591474 DOI: 10.1212/WNL.0000000000010042] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
50 Senkevich K, Gan-or Z. Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics. Parkinsonism & Related Disorders 2020;73:60-71. [DOI: 10.1016/j.parkreldis.2019.11.015] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 22.5] [Reference Citation Analysis]
51 Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, Strafella AP, Singleton AB, Barker RA, Kieburtz K, Olanow CW, Lozano A, Kordower JH, Cedarbaum JM, Brundin P, Standaert DG, Lang AE. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology 2020;94:481-94. [PMID: 32102975 DOI: 10.1212/WNL.0000000000009107] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 32.0] [Reference Citation Analysis]
52 Pará C, Bose P, Pshezhetsky AV. Neuropathophysiology of Lysosomal Storage Diseases: Synaptic Dysfunction as a Starting Point for Disease Progression. J Clin Med 2020;9:E616. [PMID: 32106459 DOI: 10.3390/jcm9030616] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
53 Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay RN, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman S, Marek K; Parkinson's Progression Markers Initiative Investigators. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. Mov Disord 2020;35:833-44. [PMID: 32073681 DOI: 10.1002/mds.27989] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 13.5] [Reference Citation Analysis]
54 Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. Neurobiol Dis 2020;137:104782. [PMID: 31991247 DOI: 10.1016/j.nbd.2020.104782] [Cited by in Crossref: 145] [Cited by in F6Publishing: 153] [Article Influence: 72.5] [Reference Citation Analysis]
55 Ji S, Wang C, Qiao H, Gu Z, Gan-Or Z, Fon EA, Chan P. Decreased Penetrance of Parkinson's Disease in Elderly Carriers of Glucocerebrosidase Gene L444P/R Mutations: A Community-Based 10-Year Longitudinal Study. Mov Disord 2020;35:672-8. [PMID: 31912918 DOI: 10.1002/mds.27971] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
56 Berge-seidl V, Toft M. Linking glucocerebrosidase gene (GBA) variants and Parkinson's disease. Genetics, Neurology, Behavior, and Diet in Parkinson's Disease 2020. [DOI: 10.1016/b978-0-12-815950-7.00005-9] [Reference Citation Analysis]
57 Krohn L, Öztürk TN, Vanderperre B, Ouled Amar Bencheikh B, Ruskey JA, Laurent SB, Spiegelman D, Postuma RB, Arnulf I, Hu MTM, Dauvilliers Y, Högl B, Stefani A, Monaca CC, Plazzi G, Antelmi E, Ferini-Strambi L, Heidbreder A, Rudakou U, Cochen De Cock V, Young P, Wolf P, Oliva P, Zhang XK, Greenbaum L, Liong C, Gagnon JF, Desautels A, Hassin-Baer S, Montplaisir JY, Dupré N, Rouleau GA, Fon EA, Trempe JF, Lamoureux G, Alcalay RN, Gan-Or Z. Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies. Ann Neurol 2020;87:139-53. [PMID: 31658403 DOI: 10.1002/ana.25629] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 15.3] [Reference Citation Analysis]
58 Bellomo G, Paciotti S, Gatticchi L, Parnetti L. The Vicious Cycle Between α ‐Synuclein Aggregation and Autophagic‐Lysosomal Dysfunction. Mov Disord 2020;35:34-44. [DOI: 10.1002/mds.27895] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 15.0] [Reference Citation Analysis]
59 Krohn L, Ruskey JA, Rudakou U, Leveille E, Asayesh F, Hu MT, Arnulf I, Dauvilliers Y, Högl B, Stefani A, Monaca CC, Beatriz A, Plazzi G, Antelmi E, Ferini-strambi L, Heidbreder A, Boeve BF, Espay AJ, De Cock VC, Mollenhauer B, Sixel-döring F, Trenkwalder C, Sonka K, Kemlink D, Figorilli M, Puligheddu M, Dijkstra F, Viaene M, Oertel W, Toffoli M, Gigli GL, Valente M, Gagnon J, Desautels A, Montplaisir JY, Postuma RB, Rouleau GA, Gan-or Z. GBA variants in REM sleep behavior disorder: a multicenter study.. [DOI: 10.1101/19010991] [Reference Citation Analysis]
60 Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-ciga S, Tan M, Gibbs R, Hernandez DG, Kumaran R, Langston R, Ponce LB, Alcalay RN, Hassin-baer S, Greenbaum L, Iwaki H, Leonard H, Grenn FP, Ruskey JA, Sabir M, Ahmed S, Makarious MB, Pihlstrøm L, Toft M, van Hilten JJ, Marinus J, Schulte C, Brockmann K, Sharma M, Siitonen A, Majamaa K, Eerola-rautio J, Tienari PJ, Pantelyat A, Hillis-trupe AE, Dawson TM, Rosenthal LS, Albert MS, Resnick SM, Ferrucci L, Morris CM, Pletnikova O, Troncoso J, Grosset D, Lesage S, Corvol J, Brice A, Noyce AJ, Masliah E, Wood N, Hardy J, Shulman LM, Jankovic J, Shulman JM, Heutink P, Gasser T, Cannon P, Scholz SW, Morris H, Cookson M, Nalls MA, Gan-or Z, Singleton AB, The 23andMe Research Team, on behalf of the International Parkinson’s Disease Genomics Consortium (IPDGC). Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia.. [DOI: 10.1101/738351] [Reference Citation Analysis]
61 Zesiewicz TA. Parkinson Disease: . CONTINUUM: Lifelong Learning in Neurology 2019;25:896-918. [DOI: 10.1212/con.0000000000000764] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
62 Franco R, Navarro G, Martínez-Pinilla E. Lessons on Differential Neuronal-Death-Vulnerability from Familial Cases of Parkinson's and Alzheimer's Diseases. Int J Mol Sci 2019;20:E3297. [PMID: 31277513 DOI: 10.3390/ijms20133297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
63 Gatto EM, Da Prat G, Etcheverry JL, Drelichman G, Cesarini M. Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency. Brain Sci 2019;9:E30. [PMID: 30717266 DOI: 10.3390/brainsci9020030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
64 Ruskey JA, Zhou S, Santiago R, Franche LA, Alam A, Roncière L, Spiegelman D, Fon EA, Trempe JF, Kalia LV, Postuma RB, Dupre N, Rivard GE, Assouline S, Amato D, Gan-Or Z. The GBA p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies. Clin Genet 2018;94:339-45. [PMID: 29920646 DOI: 10.1111/cge.13405] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]